Tip 2 Diabetes Mellitus ve Alzheimer Hastalığı Ortak Tedavi Edilebilir Mi?

Year 2018, Volume: 1 Issue: 1, 20 - 27, 15.05.2018

Beril Kadıoğlu Turgay Çelik

Abstract

Klinik,
biyokimyasal ve görüntüleme araştırmaları, Tip 2 Diabetes Mellitus (T2DM)’de
yüksek glikoz düzeylerinin, Alzheimer Hastalığı’ndaki (AH) bilişsel işlev
bozukluğuyla ilişkili olabileceğini göstermiştir. İki hastalık arasında
obezite, dislipidemi, insülin direnci ve sedanter yaşam alışkanlıkları ortak
risk ve etiyolojik faktörler olarak tanımlanmıştır. Bu durumda, yaşam tarzı
değişiklikleri ve farmakolojik ajanların kullanılması ile bu iki hastalığın
ilerlemesi önlenebilir veya geciktirilebilir. T2DM tedavisinde kullanılan başta
İnsülin, Metformin, Peroksizom Proliferatör-Aktive Reseptörler (PPAR)
agonistleri, Glukagon Benzeri Peptid-1 Reseptör agonistleri ve Dipeptidil Peptidaz-4
inhibitörleri gibi farmakolojik ajanların, AH’de ortaya çıkan bilişsel
bozukluklar üzerine koruyucu etkiler gösterdikleri gözlenmiştir.

Keywords

İnsülin Rezistansı, Alzheimer HastalığI

References

• 1. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Nomiyama K, Kawano H, Ueda K. Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology 1995; 45: 1161-1168. 2. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, Kanba S, Kiyohara Y. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 2011; 77: 1126-1134. 3. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O’Brien PC, Palumbo PJ. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol 1997; 145: 301-308. 4. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-1942. 5. Kawamura T, Umemura T, Hotta N. Cognitive impairment in diabetic patients: Can diabetic control prevent cognitive decline? J Diabetes Investig 2012; 3: 413-423. 6. Thambisetty M, Jeffrey Metter E, Yang A, Dolan H, Marano C, Zonderman AB, Troncoso JC, Zhou Y, Wong DF, Ferrucci L, Egan J, Resnick SM, O’Brien RJ. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol 2013; 70: 1167-1172. 7. Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, Haneuse S, Craft S, Montine TJ, Kahn SE, McCormick W, McCurry SM, Bowen JD, Larson EB. Glucose levels and risk of dementia. N Engl J Med 2013; 369: 540-548. 8. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet 2012; 379: 2291-2299. 9. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORDMIND) trial. Diabetes Care 2009; 32: 221-226. 10. Umegaki H, Kawamura T, Mogi N, Umemura T, Kanai A, Sano T. Glucose control levels, ischaemic brain lesions, and hyperinsulinaemia were associated with cognitive dysfunction in diabetic elderly. Age Ageing 2008; 37: 458-461. 11. Rizzo MR, Marfella R, Barbieri M, et al. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care 2010; 33: 2169-2174. 12. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301: 1565-1572. 13. Jacobson AM, Musen G, Ryan CM, et al. Longterm effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356: 1842-1852. 14. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, Sekita A, Suzuki SO, Kanba S, Kiyohara Y, Iwaki T. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 2010; 75: 764-770. 15. Gray SM, Meijer RI, Barrett EJ. Insulin regulates brain function, but how does it get there? Diabetes 2014; 63: 3992-3997. 16. Craft S. The role of insulin dysregulation in aging and Alzheimer’s disease. In: Craft S, Christen Y, editors. Diabetes, Insulin and Alzheimer’s Disease. Berlin: Springer-Verlag Berlin Heidelberg, 2010: 109-127. 17. Ding J, Strachan MW, Reynolds RM, et al. Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 2010; 59: 2883-2889. 18. de Bresser J, Reijmer YD, van den Berg E, et al. Microvascular determinants of cognitive decline and brain volume change in elderly patients with type 2 diabetes. Dement Geriatr Cogn Disord 2010; 30: 381-386. 19. Ikram MK, Cheung CY, Wong TY, Chen CP. Retinal pathology as biomarker for cognitive impairment and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2012; 83: 917-922. 20. Neumann KF, Rojo L, Navarrete LP, Farías G, Reyes P, Maccioni RB. Insulin resistance and Alzheimer’s disease: molecular links & amp; clinical implications. Curr Alzheimer Res 2008; 5: 438-447. 21. Banks WA. The source of cerebral insulin. Eur J Pharmacol 2004; 490: 5-12. 22. Florant GL, Singer L, Scheurink AJ, Park CR, Richardson RD, Woods SC. Intraventricular insulin reduces food intake and body weight of marmots during the summer feeding period. Physiol Behav 1991; 49: 335-338. 23. Marfaing P, Penicaud L, Broer Y, Mraovitch S, Calando Y, Picon L. Effects of hyperinsulinemia on local cerebral insulin binding and glucose utilization in normoglycemic awake rats. Neurosci Lett 1990; 115: 279-285. 24. Hasselbalch SG, Knudsen GM, Videbaek C, et al. No effect of insulin on glucose bloodbrain barrier transport and cerebral metabolism in humans. Diabetes 1999; 48: 1915-1921. 25. Kern W, Born J, Schreiber H, Fehm HL. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes 1999; 48: 557-563. 26. Schäfer M, Erdö SL. Development of glutamate neurotoxicity in cortical cultures: induction of vulnerability by insulin. Brain Res Dev Brain Res 1991; 62: 293-296. 27. Di Carlo M, Pasquale Picone P, Carrotta R, Giacomazza D, Biagio S. Alzheimer’s disease and type 2 diabetes: different pathologies and same features. In: Zimering M, editor. Topics in the prevention, treatment and complications of type 2 diabetes. Croatia: INTECH Open Access Publisher, 2011 [DOI: 10.5772/23490]. 28. Sridhar GR, Thota H, Allam AR, Suresh Babu C, Siva Prasad A, Divakar Ch. Alzheimer’s disease and type 2 diabetes mellitus: the cholinesterase connection? Lipids Health Dis 2006; 5: 28. 29. Xu S. Aggregation drives “misfolding” in protein amyloid fiber formation. Amyloid 2007; 14: 119-131. 30. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment? Br J Clin Pharmacol 2011; 71: 365-376. 31. Sridhar GR, Rao AA, Srinivas K, Nirmala G, Lakshmi G, Suryanarayna D, Rao PV, Kaladhar DG, Kumar SV, Devi TU, Nitesh T, Hanuman T. Butyrylcholinesterase in metabolic syndrome. Med Hypotheses 2010; 75: 648-651. 32. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009; 326: 1005-1007. 33. Blasco G, Puig J, Daunis-I-Estadella J, et al. Brain iron overload, insulin resistance, and cognitive performance in obese subjects: a preliminary MRI case-control study. Diabetes Care 2014; 37: 3076-3083. 34. Serbedžija P, Ishii DN. Insulin and insulin-like growth factor prevent brain atrophy and cognitive impairment in diabetic rats. Indian J Endocrinol Metab 2012; 16: S601-S610. 35. Sridhar GR, Nirmala G, Apparao A, et al. Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach. Lipids Health Dis 2005; 4: 18. 36. Sridhar GR, Nirmala G. Inborn errors in lipid metabolism. In: Lipid disorders. Tripathy BB, Das S, editors. Association of Physicians of India. Mumbai: API College of Physicians, 2002: 59-80. 37. Manoharan I, Boopathy R, Darvesh S, Lockridge O. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta 2007; 378: 128-135. 38. Diamant S, Podoly E, Friedler A, Ligumsky H, Livnah O, Soreq H. Butyrylcholinesterase attenuates amyloid fibril formation in vitro. Proc Natl Acad Sci USA 2006; 103: 8628-8633. 39. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in lateonset confirmed Alzheimer’s disease. Hum Mol Genet 1997; 6: 1933-1936. 40. Pohanka M. Butyrylcholinesterase as a biochemical marker. Bratisl Lek Listy 2013; 114: 726-734 [PMID: 24329513]. 41. Shenhar-Tsarfaty S, Bruck T, Bennett ER, et al. Butyrylcholinesterase interactions with amylin may protect pancreatic cells in metabolic syndrome. J Cell Mol Med 2011; 15: 1747-1756. 42. Rao AA, Siva Reddy C, Sridhar GR, et al. Enhanced butyrylcholinesterase activity may be the common link in triggering low-grade systemic inflammation and decrease in cognitive function in diabetes mellitus and Alzheimer’s disease. CurrNutr Food Sci 2008; 4: 213-216 . 43. Rao AA, Sridhar GR, Das UN. Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer’s disease. Med Hypotheses 2007; 69: 1272-1276. 44. Sridhar GR. Proteins of the esterase family: patents for some proteins in search of metabolic functions. Recent Patents on Biomarkers 2011; 1: 205-212. 45. Kaiser J. The hunt for missing genes. Science 2014; 344: 687-689 . 46. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11: 131-145. 47. Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab 2012; 97: 366-376. 48. Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and “isoglycemic” intravenous glucose. Diabetes 2014; 63: 663-674. 49. Strittmatter WJ. Alzheimer’s disease: the new promise. J Clin Invest 2012; 122: 1191. 50. Işık AT, Çelik T, Ulusoy G. et al. Curcumin ameliorates impaired insulin/IGF signalling and memory deficit in a streptozotocin-treated rat model. Age (Dordr). 2009 Mar; 31(1): 39–49. 51. Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA. Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and “isoglycemic” intravenous glucose. Diabetes 2014; 63: 663-674. 52. Craft S, Baker LD, Montine TJ, et al. Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment. Arch Neurol. 2012;69(1): 29–38. 53. Chen Y, Zhou K, Wang R, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer’s amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 2009; 106: 3907-3912. 54. Sebastião I, Candeias E, Santos MS, et al. Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for 55. Dementia. Front Endocrinol (Lausanne) 2014; 5: 110.